Xuanzhu Bio-B has been included in the list of eligible stocks for Stock Connect; Changfeng Pharmaceuticals has been added to the list of eligible securities for both Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect.
Material Matters:
Hengrui Pharma (01276): Adebrelimab Injection Receives Approval for Clinical Trial Notification
Anwell Food (02648) plans to increase capital investment in its Henan subsidiary by 1.2 billion yuan.
Xuanzhu Bio-B (02575) has been included in the list of eligible stocks for trading under the Stock Connect program.
PegBio-B (02565): PegBio's new-generation GLP-1 (CR059) achieves one-month clinical observation results in its first human trial.
Changfeng Pharmaceuticals (02652) has been included in the list of eligible securities for trading under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs.
Binhai Investment (02886) has been provided with a multicurrency term loan facility of up to 450 million US dollars and 173 million yuan.
And誉-B (02256): The Lancet published the results of the global Phase III MANEUVER study for Beiji Mai.
Operating Performance:
Yuexiu Property (00123) reported cumulative contractual sales of approximately 7.106 billion yuan in the first two months.
Mengniu Dairy (02319) expects the annual profit attributable to shareholders to be approximately RMB 1.4 billion to RMB 1.6 billion.
Dongfeng Group (00489) reported cumulative automobile sales of 228,518 units for the first two months, representing a year-on-year increase of approximately 1.2%.
Shangmei Co., Ltd. (02145) has announced a profit increase, expecting net profits for the fiscal year 2025 to range from approximately RMB 1.14 billion to RMB 1.16 billion, representing a year-over-year growth of about 41.9% to 44.4%.
Longfor Group (00960) achieved total contractual sales of 4.45 billion yuan in the first two months.
ZTE Corporation (00763) announced its 2025 annual performance, with a net profit attributable to shareholders of 5.618 billion yuan, representing a year-on-year decrease of 33.32%.
Huishang Bank (03698) issued a positive profit forecast, with a net profit of approximately 16.93 billion yuan in 2025, representing a year-on-year increase of approximately 6.3%.
Sun Hung Kai & Co. (00086) issued a profit alert, expecting consolidated net profit attributable to shareholders for the fiscal year 2025 to be no less than 1.5 billion Hong Kong dollars.
